Pfizer. has been granted a patent for a novel antibody-drug conjugate that includes a tripeptide designed for selective cleavage by tumor tissue, enhancing drug release and biodistribution in tumors compared to normal tissues. The conjugate targets CD30, potentially improving therapeutic outcomes. GlobalData’s report on Pfizer gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Pfizer, Cancer treatment biomarkers was a key innovation area identified from patents. Pfizer's grant share as of June 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody-drug conjugate targeting cd30 for tumor treatment
The granted patent US12036286B2 outlines an innovative antibody-drug conjugate (ADC) specifically designed to target CD30, a protein often associated with certain malignancies. The primary claim details the structure of the ADC, which includes an antigen-binding protein or its fragment that binds to CD30. Notably, the patent specifies that the antigen-binding protein can be the cAC10 variant. Additional claims elaborate on the composition of the antigen-binding protein, including specific hypervariable regions (HVRs) with defined amino acid sequences, and the potential for the protein to be a monoclonal, chimeric, or humanized antibody. The claims also encompass various fragment types, such as Fab and scFv, which can be utilized in the ADC formulation.
Furthermore, the patent includes claims for a pharmaceutical composition that incorporates the ADC along with a pharmaceutically acceptable carrier. It also describes a method for treating diseases or conditions that express CD30 by administering an effective amount of the ADC to individuals in need. This approach highlights the therapeutic potential of the ADC in targeting CD30-expressing diseases, which may include certain types of lymphomas and other malignancies, thereby offering a targeted treatment option that could enhance efficacy while minimizing off-target effects.
To know more about GlobalData’s detailed insights on Pfizer, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
